๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 130 Florida 117 Georgia 69 Colorado 64 Illinois 63
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca230 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC130 Novartis Pharmaceuticals113 Clear sponsor filter
State
California130 Florida117 Georgia69 Colorado64 Illinois63
All 48 states
Target enrolment
to
130 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-12-13
Active, closed
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
NCT04776252HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
2,000
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Missouri, New Jersey
2021-09-15
Active, closed
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
730
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Michigan, New York
2021-08-18
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC
Phase 2
355
California, Illinois, Iowa, Maryland, Massachusetts, Michigan, Missouri, New York
2021-08-12
Active, closed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
531
Arkansas, California, Florida, Indiana, Kentucky, Missouri, Montana, New York
2021-08-05
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-06-18
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 3
815
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Kentucky, Maryland
2021-05-12
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Arizona, California, Colorado, Florida, Indiana, Iowa, Kentucky, New York
2021-04-21
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,854
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Arkansas, California, Colorado, Kentucky, Minnesota, New Jersey, North Dakota, Texas
2021-04-05
Active, closed
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
NCT04708041Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
700
California, Florida, South Carolina, Texas, Washington
2021-03-15
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
747
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2021-02-25
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2021-01-10
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
California, Connecticut, Illinois, Iowa, Michigan, New York, North Carolina, Pennsylvania
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
California, Connecticut, Illinois, Iowa, Michigan, New York, North Carolina, Pennsylvania
2020-12-16
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naรฏve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
672
Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kentucky, Louisiana
2020-12-08
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
870
Alabama, Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Michigan
2020-07-06
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Alabama, California, Colorado, District of Columbia, Georgia, Illinois, Louisiana, Maryland
2020-02-27
Active, closed
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
6,033
California, Florida, Georgia, Idaho, Kansas, Kentucky, Missouri, Nevada
2020-02-27
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naรฏve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 1/2
450
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Observational
1,065
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Active, closed
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895Urinary Bladder Cancer, Muscle-invasive
Merck Sharp & Dohme LLC
Phase 3
595
Alabama, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois, Indiana
2019-07-24
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2018-12-24
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
Merck Sharp & Dohme LLC
Phase 3
714
California, Colorado, District of Columbia, Florida, Idaho, Illinois, Kansas, Kentucky
2018-12-17
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
Merck Sharp & Dohme LLC
Phase 2
329
Arizona, California, Colorado, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2018-12-12
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
Merck Sharp & Dohme LLC
Phase 3
976
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2018-09-12
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2018-08-21
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana
2018-04-24
Active, closed
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Phase 2
340
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2018-04-09
Rows per page Showing 101–130 of 130
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.